Key Highlights

  • DBV Technologies submitted a Biologics License Application for its VIASKIN Peanut Patch targeting children aged 4 to 7.
  • The company requested Priority Review to accelerate the regulatory timeline.
  • DBV holds $165.7 million in cash, providing runway through the third quarter of 2027.
  • Manufacturing remediation at its Fareva facility, following an FDA Warning Letter, remains the primary operational risk ahead of launch.

BLA Filed for Pediatric Peanut Allergy Treatment

DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch, aimed at children between the ages of 4 and 7. The company requested Priority Review status for the filing, a designation that, if granted, would shorten the standard review timeline and could accelerate a path to potential approval and commercial launch.

Cash Position and Manufacturing Risk

DBV ended the period with $165.7 million in cash, which the company said provides operational runway through the third quarter of 2027, giving it a multi-year window to advance the program without an immediate need for additional financing. The primary risk to the regulatory and commercial timeline remains manufacturing remediation at its Fareva facility, following an FDA Warning Letter issued to the site. Resolving these manufacturing concerns ahead of a potential approval will be an important milestone to watch, since unresolved quality issues at a manufacturing site can delay or complicate a BLA review even when clinical data is supportive.

What age group is DBV Technologies' VIASKIN Peanut Patch BLA targeting?

The Biologics License Application targets children between the ages of 4 and 7.

What is the main risk to DBV Technologies' commercial launch timeline?

Manufacturing remediation at its Fareva facility, following an FDA Warning Letter, is the primary operational risk ahead of a potential launch.